Company: SUPN
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001356576-25-000055
Chunk: 83

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 83
---
 30, 2025 (unaudited):Vested and expected to vest7,527,414 $31.04 6.1Exercisable 4,800,080 $30.16 4.6As of December 31, 2024:Vested and expected to vest6,719,073 $30.44 5.9Exercisable4,137,283 $29.54 4.4Restricted Stock UnitsThe following table summarizes restricted stock unit (RSU) activities:Number ofRSUsWeighted AverageGrant Date Fair Value per ShareNonvested, December 31, 2024378,165 $32.48 Granted172,725 $33.50 Vested(136,673)$32.33 Forfeited(9,262)$32.30 Nonvested, June 30, 2025 (unaudited)404,955 $32.97 

16

Performance Share Units The following table summarizes performance share unit (PSU) activities:Performance-Based UnitsMarket-Based UnitsTotal PSUs Number of PSUsWeightedAverageGrant Date Fair Value per ShareNumber of PSUsWeightedAverageGrant Date Fair Value per ShareNumber of PSUsWeightedAverageGrant Date Fair Value per ShareNonvested, December 31, 2024324,685 $28.80 20,000 $28.63 344,685 $28.79 Granted246,496 $32.84 — $— 246,496 $32.84 Vested(114,415)$30.52 — $— (114,415)$30.52 Forfeited(37,550)$30.42 — $— (37,550)$30.42 Nonvested, June 30, 2025 (unaudited)419,216$30.56 20,000$28.63 439,216$30.47 

10.    Earnings per Share

The following table sets forth the computation of basic and diluted earnings per share for the three and six months ended June 30, 2025 and 2024 (dollars in thousands, except share and per share amounts):Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024(unaudited)(unaudited)Numerator:Net earnings$